NAD+ dosage and side effects in the trials

Amounts tested

The NR blood study tested 100, 300 and 1000 mg/day for 8 weeks in healthy overweight adults. The multicentre NMN study tested 300, 600 and 900 mg/day for 60 days. A separate NMN trial in postmenopausal women with prediabetes used 250 mg/day for 10 weeks.

The 2025 review covers a wider set of studies, including NMN amounts up to 1200 mg and NR amounts up to 3000 mg. Those upper figures describe what was investigated. They establish neither an ideal amount nor the safety of taking it in a different setting.

For intravenous NAD+, the cognition pilot used 750 mg/day for 5 consecutive days. Arranging these unrelated experiments into a ladder from small to large seems pointless to me. The study question matters more than the position on that ladder. The amounts remain attached to their original participants and measurements.

NAD+ side effects in oral trials

In the eight-week NR trial, no flushing was reported and adverse events did not differ significantly from placebo. LDL cholesterol did not rise, and the measured markers of one-carbon metabolism were undisturbed. In the 60-day NMN trial, no safety issues were reported at the tested amounts. The rare-disease NR review reports no moderate or severe adverse events across the reviewed trials.

Those observations offer useful short-term reassurance within their settings. The participants, duration and checks define what that reassurance covers. Effects that take years to emerge, interactions with other medicines and health conditions outside the study populations remain unresolved.

Infusion discomfort and contamination

Chest or abdominal discomfort, flushing and nausea have been reported when intravenous NAD+ is given too quickly. Symptoms generally ended when the infusion finished in those reports. An individual’s course cannot be predicted from that observation.

There is also a separate manufacturing concern. FDA recalled a compounded NAD+ injection for elevated bacterial endotoxin and assigned its most serious designation, Class I. Compounded injections are unapproved, and contamination adds a risk beyond the molecule’s own effects. The distinction deserves attention: tolerating an ingredient in an experiment says little about the quality of another preparation.

NAD+ half life and plasma clearance

The plasma-clearance work describes near-complete removal of added NAD+ from plasma within roughly two hours of infusion starting. Plasma is the liquid part of blood. That observation leaves the destination of the added material and the duration of any useful effect unresolved; it does not establish a whole-body treatment half-life.

Oral precursor trials measured blood increases over days or weeks during continued administration. Those observations concern different forms, routes and blood measurements. They leave appointment timing unresolved. They are better treated as questions about what was measured and where.

Cancer and long-term questions

The metabolism review and human-ageing review describe context-dependent questions around NAD+ and cancer. NAD+ supports proliferating cells, creating a theoretical concern that extra supply could also support an existing cancer. The biology has different roles in different cancers; a general claim of harmlessness runs ahead of the evidence.

I would give long-term clinical outcomes far more weight than a temporarily higher blood result. The ageing review finds that longevity and disease-prevention benefits in people remain unproved.

Supplement status, quality and other routes

NAD+ has no FDA drug approval for treating disease. NMN’s supplement status has been contested: FDA’s position described in the current record concerns prior investigation as a drug and exclusion from the dietary-supplement definition. That regulatory dispute is distinct from a ban. NAD+ and its precursors are not prohibited by WADA.

Supplement purity and actual contents vary, and outside laboratory testing is not assured. NAD+ and NMN take up moisture and degrade in heat or damp conditions. Patches, creams and mouth or nose sprays have little controlled human evidence compared with the oral precursor trials. The NAMPT review describes daily rhythms in NAD+ recycling. Trials have established no best morning or evening treatment time.

The useful next step in understanding a claim is to identify its actual ingredient and outcome. The NMN-versus-NR page does that comparison, and the study list contains the research used here.